These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38421659)

  • 41. Discovery of novel glucagon-like peptide 1/cholecystokinin 1 receptor dual agonists.
    Chenxu Z; Lidan S; Guoqiang H; Binbin G; Ting W; Xiaoyi S; Qian L
    Eur J Pharm Sci; 2024 Aug; 199():106818. PubMed ID: 38801960
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
    Guo XH
    Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
    [TBL] [Abstract][Full Text] [Related]  

  • 43. How do drugs such as Ozempic work for weight loss . . . and everything else?
    Guenot M
    BMJ; 2024 Aug; 386():q1767. PubMed ID: 39159969
    [No Abstract]   [Full Text] [Related]  

  • 44. Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity?
    Kaplan JM; Zaman A; Abushamat LA
    Curr Cardiol Rep; 2024 Sep; 26(9):1011-1019. PubMed ID: 39031282
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New therapies for diabesity.
    Bailey CJ
    Curr Diab Rep; 2009 Oct; 9(5):360-7. PubMed ID: 19793506
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity.
    Maselli DB; Camilleri M
    Adv Exp Med Biol; 2021; 1307():171-192. PubMed ID: 32077010
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity.
    Jensterle M; Janež A
    Horm Res Paediatr; 2023; 96(6):599-608. PubMed ID: 34852347
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions.
    Jalleh RJ; Rayner CK; Hausken T; Jones KL; Camilleri M; Horowitz M
    Lancet Gastroenterol Hepatol; 2024 Oct; 9(10):957-964. PubMed ID: 39096914
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes.
    Scheen AJ
    Ann Endocrinol (Paris); 2023 Apr; 84(2):316-321. PubMed ID: 36639119
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dispensing of Glucagon-Like Peptide-1 Receptor Agonists to Adolescents and Young Adults, 2020-2023.
    Lee JM; Sharifi M; Oshman L; Griauzde DH; Chua KP
    JAMA; 2024 Jun; 331(23):2041-2043. PubMed ID: 38776113
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches.
    Morissette A; Mulvihill EE
    J Pharm Pharm Sci; 2024; 27():13065. PubMed ID: 38903652
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
    Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
    Torekov SS
    Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921
    [No Abstract]   [Full Text] [Related]  

  • 57. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.
    Burcelin R; Gourdy P
    Obes Rev; 2017 Jan; 18(1):86-98. PubMed ID: 27636208
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes.
    Mayfield K; Siskind D; Winckel K; Russell AW; Kisely S; Smith G; Hollingworth S
    J Psychopharmacol; 2016 Mar; 30(3):227-36. PubMed ID: 26801056
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Investigational glucagon-like peptide-1 agonists for the treatment of obesity.
    Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1167-79. PubMed ID: 27563838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.